Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients, but significance of this observation is question...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Verger, Emmanuelle, Soret-Dulphy, Juliette, Maslah, Nabih, Roy, Lydia, Rey, Jerome, Ghrieb, Zineb, Kralovics, Robert, Gisslinger, Heinz, Grohmann-Izay, Barbara, Klade, Christoph, Chomienne, Christine, Giraudier, Stéphane, Cassinat, Bruno, Kiladjian, Jean-Jacques
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172224/
https://ncbi.nlm.nih.gov/pubmed/30287855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0133-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia